Health Care Innovation
2021 was a landmark year for biotechnology and pharmaceutical innovation, from COVID-19 vaccines and the wide array of novel modalities advancing through the pipeline, to the first approvals for Alzheimer’s disease and a drug targeting a previously “hard-to-drug” tumor proliferation protein, KRAS. 2022 will be an inflection point for novel modalities and novel targets as these agents face off in competitive diseases and key approvals and data readouts loom.
What we’re watching
- Modality Face Off
- Gene Therapy and Gene Editing
- Infectious Disease
- Alzheimer’s Disease
- Psychedelics
- Targeted Oncology
- Novel Immune-Oncology Targets
- Gene and Cell Therapy Tools
“2022 will be an inflection point for novel modalities and novel targets as these agents face off in competitive diseases and key approvals and data read outs loom.”
Cowen Research